Get info on Pharmeasy Board of Directors before buying, selling and investing - Read our Research report on Pharmeasy share & Information like - Pharmeasy Balance Sheet, Total Asset, Current Assets etc.

Pharmeasy Balance Sheet

  • Current Ratio

    The current ratio of the company has been 1.63 in FY'21. This is because the current assets of the company have increased by 177% in FY'21 over FY'20 which is because of a large increase in the trade receivables as well as inventory of the company. On the other hand the current liabilities have increased by 665% in FY'21 over FY'20 which is mainly due to the increase in short term borrowing of the company.

  • Total Debt to Equity

    The company's debt to equity ratio has been 0.24 in FY'21. Even though the company has taken a cash credit loan from a bank as well as taken unsecured loans in FY'21 increasing its total debt, the company's total equity has increased a lot due to a massive increase of INR 3,083 Cr in its reserves and surplus further increasing the other equity of the company. As a result the company has a low debt to equity ratio.

Financial Year

Cash & Short Term Investments
Total Receivables
Total Inventory
Prepaid Expenses
Current Investments
Other Current Financial Assets
Loan & Advances
Deferred Tax Assest
Current Assets
Net Property/Plant/Equipment
Goodwill
Other Intangible Assets
Intangible Assets Under Development
Long Term Investments
Deferred Tax Assets (Net)
Other Non Current Assets
Non Current Assets
Total Assets
Accounts Payable
Total Deposits
Current Portion of Long Term Debt
Unearned Revenue
Current Portion of Leases
Other Current Liabilities
Current Liabilities
Total Long Term Debt
Long Term Portion of Leases
Deferred Tax Liabilities (Net)
Other Non Current Liabilities
Non Current Liablities
Total Liabilities
Common Stock
Other Equity
Reserves & Surplus
Additional Paid-in Capital
Retained Earnings
Minority Interest
Treasure Stock
Comprehensive Inc. & Other
Total Equity
Total Common Shares Outstanding
Total Liabilities & Shareholder's Equity
FY 2020

58.53

47.26

115.95

1.81

0.74

98.26

153.15

-

475.69

20.79

0.68

42.13

0.35

6.93

18.33

7.57

96.78

572.47

70.97

-

27.21

-

7.52

21.84

127.54

152.66

33.16

-

12.87

198.69

326.23

0.01

246.23

-

-

-

-

-

-

246.24

10,000

572.47

FY 2021

323.18

358.29

405.62

11.89

0.81

172.59

45.52

0.24

1,318.11

156.47

3,192.16

66.86

-

0.11

1.68

169.97

3,587.23

4,905.34

365.55

-

353.24

-

19.14

238.29

976.21

232.15

79.57

20.77

15.47

347.96

1,324.17

25.62

3,413.76

-

-

-

141.8

-

-

3,581.18

2,56,20,120

4,905.34

FY 2022

329.22

860.85

761.24

18.9

126.15

245.52

160.33

-

2,502.21

567.83

7,095.55

663.51

1

311.8

16.82

239.62

8,896.12

11,398.33

458.88

-

2,485.35

-

38.25

779.12

3,761.61

100.07

150.56

197.76

165.85

614.24

4,375.85

614.2

6,083.08

-

-

-

325.2

-

-

7,022.48

6,14,20,41,070

11,398.33

Shares outstanding numbers in None. Other numbers in ₹ Cr

* denotes current year's data

  • Pharmeasy Annual Reports

2021

Jefferies Research report on API Holding(Pharmeasy).

2021

Annual Report - FY21

2022

Annual Report - FY22

API Holdings(Pharmeasy) DRHP